辅助生殖技术治疗与卵巢癌风险——一项全国性人群队列研究
该研究基于丹麦全国登记数据,纳入1994-2015年接受辅助生殖技术(ART)治疗的58 472名女性,并按年龄匹配625 330名未治疗女性,随访至多22年。ART治疗女性卵巢癌风险升高(HR 1.20,95%CI 1.10-1.31),且随时间减弱;子宫内膜异位症者风险升高(HR 3.78,95%CI 2.45-5.84),无子宫内膜异位症者未见风险升高。
要点
- ART治疗女性整体卵巢癌风险轻度升高(HR 1.20,95%CI 1.10-1.31),随时间减弱。
- 合并子宫内膜异位症的ART治疗女性卵巢癌风险升高(HR 3.78,95%CI 2.45-5.84)。
- 无子宫内膜异位症者接受ART治疗未与卵巢癌风险升高相关。
核心结论
- ART治疗女性中未发现卵巢癌风险整体升高,但合并子宫内膜异位症的ART治疗女性例外。
- 无子宫内膜异位症者接受ART治疗未与卵巢癌风险升高相关,这一结果令人安心。
- ART治疗是否增加子宫内膜异位症女性的卵巢癌风险需进一步研究。
研究设计与样本
- 基于丹麦IVF登记库的全国性人群队列研究,纳入1994-2015年接受ART治疗的女性。
- 通过个人身份识别号链接丹麦癌症登记库和社会人口登记库数据。
- 所有ART治疗女性按年龄与女性背景人群随机样本匹配,随访至多22年。
- 排除后共纳入58 472名ART治疗女性和625 330名未治疗女性,均无既往恶性肿瘤。
- 采用多变量Cox回归分析,校正教育水平、婚姻状况、产次和治疗年份,结果以风险比(HR)及相应CI表示。
主要发现
- 随访期间(平均9.7年)共393名(0.06%)女性被诊断为卵巢癌。
- ART治疗女性卵巢癌风险升高(HR 1.20,95%CI 1.10-1.31),该风险随时间减弱。
- 女性因素不孕的ART治疗女性风险升高(HR 1.36,95%CI 1.25-1.48),而无女性因素不孕者风险较低(HR 0.87,95%CI 0.76-1.00)。
- 合并子宫内膜异位症的女性风险升高(HR 3.78,95%CI 2.45-5.84)。
- 合并多囊卵巢综合征、其他女性不孕原因及不明原因不孕的ART治疗女性未发现风险升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- ART治疗与卵巢癌之间的关联可能受ART治疗期间多次超声扫描导致的检出增加影响。
- ART治疗是否增加子宫内膜异位症女性的卵巢癌风险需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does hormone stimulation during assisted reproductive technology (ART) treatment increase the risk of ovarian cancer? SUMMARY ANSWER: No increased risk of ovarian cancer was found among ART-treated women, with the exception of ART-treated women with endometriosis. WHAT IS KNOWN ALREADY: Previous studies on the association between ovarian stimulation during ART and ovarian cancer have shown conflicting results. The risk of ovarian cancer varies according to the cause of infertility, and only a few studies on ART treatment and risk of ovarian cancer have had sufficient data to address this issue. Endometriosis has been linked to an increased risk of ovarian cancer. STUDY DESIGN, SIZE, DURATION: Women undergoing ART treatment during 1994-2015 were registered in the Danish IVF register. Data were linked with data from the Danish Cancer Register and socio-demographic population registers using an individual person identification number assigned to people residing in Denmark. PARTICIPANTS/MATERIALS, SETTING, METHODS: All women undergoing ART treatment were age-matched with a random sample of the female background population and followed for up to 22 years. After relevant exclusions, the population consisted of 58 472 ART-treated women and 625 330 untreated women, all with no previous malignancies. Ovarian cancer risk was assessed using multivariable cox regression analyses with adjustment for educational level, marital status, parity and treatment year. Results are shown as hazard ratios (HRs) with corresponding CIs. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 393 (0.06%) women were diagnosed with ovarian cancer during follow-up (mean 9.7 years). Women treated with ART had an increased risk of ovarian cancer (HR 1.20, 95% CI 1.10-1.31), which diminished over time. The increased risk was apparent among women with female factor infertility (HR 1.36, 95% CI 1.25-1.48), whereas no female factor infertility was associated with a lower risk (HR 0.87, 95% CI 0.76-1.00). The risk was increased among women with endometriosis (HR 3.78, 95% CI 2.45-5.84), whereas no increased risk was found among ART-treated women with polycystic ovary syndrome, other female causes of infertility and unexplained infertility. LIMITATIONS, REASONS FOR CAUTION: The association between ART treatment and ovarian cancer is likely influenced by increased detection due to multiple ultrasound scans during ART treatment. WIDER IMPLICATIONS OF THE FINDINGS: Undergoing ART treatment without the presence of endometriosis was not associated with an increased risk of ovarian cancer, which is reassuring. Whether ART treatment increases the risk of ovarian cancer among women with endometriosis needs further investigation. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by a PhD grant to D.V. from the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Funding for establishing the Danish National ART-couple II cohort was achieved from Ebba Rosa Hansen Foundation. The funders had no influence on data collection, analyses or results presented. The authors have no conflicts of interest to declare.
引用
- Vassard D, Schmidt L, Glazer CH, et al. Assisted reproductive technology treatment and risk of ovarian cancer-a nationwide population-based cohort study. Hum Reprod. 2019. PMID: 31600391. doi:10.1093/humrep/dez165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。